Investing.comCodex · 实盘不做把握 7/10
北京时间·🕒 发布 05:33:07时区推断·⟳ 抓取 05:33:34·⚡ 决策 07-25 05:34:39 +1m05s·95.1 天前
中国苏轩堂完成约900万美元注册直接发行，前一日已因稀释风险暴跌
公司以每单位2.00美元发行450万单位并附带认股权证，融资规模约900万美元，且SEC补充招股书显示还登记大量认股权证相关股份，稀释压力明确。
📄 原文Investing.com↗ 原文
China SXT Pharmaceuticals raises $9M in direct offering
Stocks post weekly losses amid widening Iran conflict, AI worries, and tariffs NEW YORK - China SXT Pharmaceuticals Inc…
不做 中国苏轩堂（SXTC.US）
注册直接发行是明确稀释利空，但定价公告已在7月23日传播并引发连续暴跌；当前完成公告缺少新增edge，且未核到Futu可借券库存，不能追空，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 公司424B5补充招股书披露以每单位2.00美元发行最多450万单位、总额最高900万美元，并登记认股权证相关股份。
- Investing.com报道融资定价并指出股价因显著稀释下跌约77%。市场反应:SXTC.US 7月23日收盘显示约-83.5%。
- 7月24日盘中报价约0.0554美元，较前日继续下跌约83.3%，说明融资稀释已被连续交易。市场反应:SXTC.US 7月24日盘中约-83%。
- 本条信号称公司已完成约900万美元注册直接发行，是前一日已公布融资的完成进展。市场反应:美股已收盘，连续交易窗口不可成交。
关键理由
- 公司以每单位2.00美元发行450万单位并附带认股权证，融资规模约900万美元，且SEC补充招股书显示还登记大量认股权证相关股份，稀释压力明确。
- 该事项最早在7月23日定价公告后已被交易，SXTC.US在7月23日收跌约83.5%，7月24日盘中继续大跌，完成公告更多是已知融资的落地确认而非新的可做空窗口。
主要风险
- 微盘股融资条款复杂且波动极端，若后续出现反弹或反向并股/合规消息，裸空风险高；本次未取得Futu借券库存，不能给可执行做空单。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-07-24 · 影响 weakens
未发现公司否认融资或撤销发行的反证；但融资利空已提前传播并大幅定价，且未取得可借券证据。
检索:SXTC registered direct offering completion counter evidence rebound financing denial July 2026 原文 ↗
原文全文
展开原文 · 1,359 字
Stocks post weekly losses amid widening Iran conflict, AI worries, and tariffs
NEW YORK - China SXT Pharmaceuticals Inc. (NASDAQ:SXTC) completed a registered direct offering of approximately $9 million, according to a press release statement issued today.
The pharmaceutical company sold 4,500,000 units to institutional investors at $2.00 per unit. Each unit consists of one Class A ordinary share and one common warrant. The warrants have an exercise price of $3.20 per Class A ordinary share, are immediately exercisable upon issuance, and will expire one year from the issuance date.
Univest Securities, LLC served as the sole placement agent for the transaction. The offering was conducted under a shelf registration statement on Form F-3 (File No. 333-291428) that was declared effective by the U.S. Securities and Exchange Commission on December 1, 2025.
China SXT Pharmaceuticals, headquartered in Taizhou City, Jiangsu Province, China, focuses on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces. The company was founded in 2005.
Univest Securities, LLC is a FINRA-registered broker-dealer firm based in New York that provides brokerage, investment banking, and wealth management services.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
NEW YORK - China SXT Pharmaceuticals Inc. (NASDAQ:SXTC) completed a registered direct offering of approximately $9 million, according to a press release statement issued today.
The pharmaceutical company sold 4,500,000 units to institutional investors at $2.00 per unit. Each unit consists of one Class A ordinary share and one common warrant. The warrants have an exercise price of $3.20 per Class A ordinary share, are immediately exercisable upon issuance, and will expire one year from the issuance date.
Univest Securities, LLC served as the sole placement agent for the transaction. The offering was conducted under a shelf registration statement on Form F-3 (File No. 333-291428) that was declared effective by the U.S. Securities and Exchange Commission on December 1, 2025.
China SXT Pharmaceuticals, headquartered in Taizhou City, Jiangsu Province, China, focuses on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces. The company was founded in 2005.
Univest Securities, LLC is a FINRA-registered broker-dealer firm based in New York that provides brokerage, investment banking, and wealth management services.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。